Germline testing, next generation sequencing, and the use of PARP inhibitor monotherapy for select patients have been part of our treatment paradigm for patients with metastatic castration-resistant ...

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas Until ...